NASDAQ
87.93USD
+0.59 (+0.68%)
We have scored 54 news catalysts on DexCom, Inc. (DXCM) over the past 12 months. The biggest single-day move next to one of them came May 15, 2026, when DXCM closed +6.6%: “Dow futures plunge 300 points: 5 things to know before market opens”. Coverage across the window leans negative (average ticker sentiment −0.24). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
33.2B
P/E
—
EPS
—
Beta
1.42
52W range
54.11-92.59
Day range
87.17–88.26
Open
87.54
Prev close
87.34
Volume
2.8M
Avg volume
5.3M
Dividend
0.00
IPO
2005-04-14
Analysts publish price targets on DXCM, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $64 to $105
as of 2026-09-02
The market is within 0% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about DexCom, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of DexCom, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for DXCM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
The price sits exactly at the median of 19 published models, agreeing with the near-consensus that roughly 12% annual revenue growth and expanding margins are already earned, while refusing to pay for the 16% upside of the bull case or accept the 29% downside of the bear case.
What the disagreement turns on
Does the expanded non-insulin Type 2 diabetes market — both the 7 million commercially insured patients and the pending 12 million Medicare lives — actually translate into accelerating unit volumes, or do GLP-1 drugs and slow consumer adoption erode the base faster than the new patients add to it; unit volume data can settle the first half, but the GLP-1 threat cannot be measured with the wired tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
